Solaroglu I, Tsubokawa T, Cahill J, Zhang J H
Department of Physiology and Pharmacology, Loma Linda University, School of Medicine, Loma Linda, CA, USA.
Neuroscience. 2006 Dec 28;143(4):965-74. doi: 10.1016/j.neuroscience.2006.09.014. Epub 2006 Nov 2.
We investigated the molecular mechanisms of the anti-apoptotic properties of granulocyte-colony stimulating factor (G-CSF) on neurons and whether G-CSF affects glial cell survival following focal cerebral ischemia in rats. Sprague-Dawley rats were subjected to a transient 90 min middle cerebral artery occlusion (MCAO) by the intraluminal occlusion technique. Rats were treated with either a single dose of G-CSF (50 microg/kg, s.c.) at the onset of reperfusion or G-CSF (50 microg/kg body weight, s.c.) was administered starting at the onset of reperfusion and followed by the administration of the same dose per day for an additional 2 days. Brains were harvested either 24 h, 72 h or 2 weeks after reperfusion for assays of infarct volume, immunohistological studies and Western blot analysis for phosphorylated signal transducer and activator of transcription 3 (pSTAT3), Pim-1, bcl-2, Bax, cytochrome c, cellular inhibitor of apoptosis protein 2 (cIAP2), and cleaved caspase-3 levels. G-CSF significantly reduced infarct volume and ameliorated the early neurological outcome. G-CSF treatment significantly up-regulated pSTAT3, Pim-1, bcl-2 expression, and down-regulated cytochrome c release to the cytosol, Bax translocation to the mitochondria, and cleaved caspase-3 levels in neurons. The activation of the STAT3 pathway was accompanied by increased cIAP2 expression in glial cells. After MCAO, G-CSF treatment increased both neuronal and glial survival by effecting different anti-apoptotic pathways which reflects the multifactorial actions of this drug. These changes were associated with remarkable improvement in tissue preservation and behavioral outcome.
我们研究了粒细胞集落刺激因子(G-CSF)对神经元抗凋亡特性的分子机制,以及G-CSF是否影响大鼠局灶性脑缺血后神经胶质细胞的存活。采用腔内闭塞技术对Sprague-Dawley大鼠进行90分钟的短暂大脑中动脉闭塞(MCAO)。在再灌注开始时,大鼠接受单剂量G-CSF(50微克/千克,皮下注射)治疗,或者从再灌注开始时给予G-CSF(50微克/千克体重,皮下注射),并在接下来的2天每天给予相同剂量。在再灌注后24小时、72小时或2周采集大脑,用于测定梗死体积、免疫组织学研究以及对磷酸化信号转导和转录激活因子3(pSTAT3)、Pim-1、bcl-2、Bax、细胞色素c、细胞凋亡抑制蛋白2(cIAP2)和裂解的半胱天冬酶-3水平进行蛋白质印迹分析。G-CSF显著减小梗死体积并改善早期神经功能结果。G-CSF治疗显著上调pSTAT3、Pim-1、bcl-2的表达,并下调细胞色素c释放到细胞质、Bax转位到线粒体以及神经元中裂解的半胱天冬酶-3水平。STAT3途径的激活伴随着神经胶质细胞中cIAP2表达的增加。MCAO后,G-CSF治疗通过影响不同的抗凋亡途径增加神经元和神经胶质细胞的存活,这反映了该药物的多因素作用。这些变化与组织保存和行为结果的显著改善相关。